Jake Strauss is a Managing Director at Warburg Pincus based in New York. He joined Warburg Pincus in 2010, and is a member of the firm’s Healthcare group. Previously, he worked in the firm’s Energy group. Prior to joining Warburg Pincus, he was in the Consumer Products and Retail Investment Banking Group at Citigroup in New York. He currently works with Aetion, Ensemble Health Partners, and Helix and has been involved with the firm’s investments in Accriva Diagnostics, Bausch & Lomb, and ReSearch Pharmaceutical Services (RPS). He was also previously a Director of Canbriam Energy, Citizen Energy, and RS Energy Group. Mr Strauss received a BA magna cum laude in Economics from Princeton University.

With an expertise in applying Design Thinking approach to Product Models, Chandeep Kaur has been consistently delivering impactful, intuitive, and user-oriented solutions across an extensive spectrum of industries, such as healthcare, public sector, retail, finance, and non-profits.

As a seasoned Product Designer, Ms Kaur plays a pivotal role as the bridge between business stakeholders and cross-functional technical teams, ensuring seamless alignment and delivery of tangible business value. What truly sets Ms Kaur apart is her profound understanding of user needs, honed through rigorous user research and empathy-driven design practices. She played a pivotal role in eliciting business requirements for the Clinical Trials website Project, transforming them into actionable prototypes. This enabled rapid ideation and MVP testing, facilitating a seamless transition to a Product Model approach focused on value and incremental delivery. Her user-centric approach not only effectively communicates solutions but also drives user engagement that directly aligns with overarching business goals.

Ms Kaur’s proficiency in design thinking methodologies empowers her to navigate complexity, uncovering valuable insights and opportunities that fuel Product innovation. By championing iterative development and fostering continuous feedback loops, she ensures that solutions evolve in sync with user needs and market dynamics.

Christina Fawcett, a certified Project Management Professional (PMP), boasts a rich career spanning over two decades in the execution of clinical trials across diverse designs, phases, and therapeutic areas. Currently, she holds the position of Director of Digital Health Delivery, where she spearheads a team responsible for the effective implementation of digital and decentralized solutions within GSK's global clinical operations portfolio. Her leadership ensures quality standards, broadens participant involvement, and minimizes operational inefficiencies. Prior to this, Christina honed her skills in study delivery within CROs, notably as a Senior Director at PRA Health Sciences. Here, she led the Decentralized Clinical Trial Operations team, pioneering DCT protocols for various sponsors, including a groundbreaking fully decentralized Phase IIIb interventional trial.

Dr Anand Subramony is Vice President of the DDCS (Delivery, Device, and Connected Solutions) group at Lilly and he provides leadership to early development of combination products and novel drug delivery technologies. Prior to Lilly, Dr Subramony was Vice President within the Biologics Engineering and Targeted Delivery group, at AstraZeneca where he led various cross-functional teams in the areas of nanomedicine, drug conjugates, and drug delivery of new modalities including implantable cell therapy devices. He also provided leadership to external innovation and CoSolve, an open innovation platform. Prior to that Dr Subramony headed the Drug Delivery & Device Development at Medimmune and built an internal team that focused on combination product development, connected devices, digital biomarkers/sensors, as well as advanced novel delivery technologies including oral peptide delivery and other novel controlled release technologies. 

In other roles, Dr Subramony was Principal Fellow and Head of Novel Delivery Technologies at Novartis (NIBR, Cambridge, MA), head of the Materials Science group at Alza /J&J (Mountain View, CA), and Director of Materials Science & Drug delivery at Dr. Reddy’s Laboratories (Bridgewater, NJ). 

With his broad experience in pharma biotech, Dr Subramony brings innovation and scientific rigor coupled with execution excellence and sense of urgency to create patient centric products. He has established and managed high-performing teams in all his roles. Dr. Subramony holds an M.S. degree in Materials Science Engineering (IIT, Bombay) and a Ph.D. degree from Purdue University. With several refereed publications and patents, he is a sought-after Key Opinion Leader in the areas of drug delivery and product development.

Chris Rodricks is a Strategic Partnerships Lead in Pfizer Ignite, a new end-to-end developmental and clinical service model for biotech innovators to help advance novel therapies to market. In the past, Chris worked in Strategy and Consulting working across the R&D continuum from idea to launch and has been involved in and led a number of efforts across the drug development value chain from organizational redesign (e.g. creation of a new clinical organization, enabling functions), integration efforts (e.g. Wyeth, Allergan) and unit level strategies (e.g. GTx operations) to productivity analyses (e.g. productivity, metrics analyses, cost per POC), forecasting (e.g. pre-launch milestone forecasting) and competitive analyses linked to overall strategic priorities. 

Chris’s career is fueled by a relentless curiosity and a passion for forging meaningful connections with the extraordinary individuals he encounters. He is a proud alumnus of Stevens Institute of Technology, where he obtained a bachelor’s degree in Chemical Biology, and Rensselaer Polytechnic Institute, where he earned his MBA.

Chris’s personal life is just as fulfilling as his professional one. He resides in Mystic, CT, with his wonderful wife, their spirited son, and two exuberant huskies, who bring joy and a touch of chaos to their home.

TBA

David Parker has spent the last 30 years working in Clinical Operations positions of increasing responsibility across all phases and many therapeutic areas of research. His experience spans big pharma such as AstraZeneca, mid-size biopharma such as Regeneron and CSL Behring, and small biotech including MacroGenics and Immunocore. Mr Parker’s focus has been equally split between studyParker delivery, capabilities development, and organizational leadership.

Peter Morley is a Clinical Sustainability Manager at Novo Nordisk A/S, leading on the decarbonisation of clinical trials globally. He is also a member of the Sustainable Markets Initiative Health Systems Task Force, collaborating with industry and academia to accelerate the decarbonisation of the clinical trials sector through shared frameworks and tools.

With a background spanning more than 25 years in clinical operations, Mr Morley has been with Novo Nordisk since 2001, taking on various roles across the clinical trial process at both local and global levels. His passion for sustainability, combined with a sharp focus on innovation and digitalisation, positions him at the forefront of setting the path for decarbonisation and driving the necessary changes to significantly lower the environmental impact of clinical trials at Novo Nordisk.

Marsha Calloway-Campbell, J.D., brings over 35 years of diverse expertise to Legacy 

Health Strategies. Her dual career as an attorney, practicing in the areas of 

Employment Law, Estate Planning and Probate Law, and a Market Research 

Consultant has proven to be successful over the years. At the helm of her consultancy 

firm, Marsha collaborated with leading Fortune 100 companies, specializing in 

Qualitative Research. Her professional experiences span across consumer-packaged 

goods, legal, pharmaceutical, and healthcare sectors, underscoring her versatility and 

depth of knowledge.

Marsha's path took a transformative turn in 2017 following her husband's multiple 

myeloma diagnosis. This personal experience reshaped her life, as she embraced the 

role of caregiver and, subsequently, a health advocate. Her dedication led her  

eventually to the role of Director of a Black Myeloma Health Initiative with a myeloma 

patient-advocacy organization.

Marsha's journey into health advocacy revealed her profound passion for health equity, 

transcending beyond myeloma. She is driven by a vision to leverage her extensive skill 

set and fervent passion to help others cultivate a legacy of health and cultural equity in 

diverse communities. At Legacy Health Strategies, Marsha is a pivotal force in 

promoting health and wellness, particularly for underserved populations by engaging 

with patients and communities of color. Her approach encompasses amplifying patient 

voices, tackling health disparities, and empowering patients with essential knowledge 

about clinical research.

Colby Wilkinson is a Principal Data Scientist at Vertex Pharmaceuticals, where he's been part of the Data Strategy & Solutions team since 2020. He previously held various Data Science roles in the National Defense, Legal, and Health Economics fields. Mr Wilkinson earned a dual degree in Quantitative Economics and Community Health from Tufts University and a master’s degree in Biostatistics from Harvard T.H. Chan School of Public Health. He currently resides in Boston with his wife and dog, Rue.

Elisa Konofagou is the Robert and Margaret Hariri Professor of Biomedical Engineering and Professor Radiology as well as Director of the Ultrasound and Elasticity Imaging Laboratory at Columbia University in New York City. Her main interests are in the development of novel theranostic and therapeutic ultrasound methods for the advancement of therapeutic ultrasound. Elisa has co-authored over 300 published articles in the aforementioned fields. Elisa Konofagou is the Robert and Margaret Hariri Professor of Biomedical Engineering. Elisa is a Member of the National Academy of Medicine (US), an Elected Fellow of the International Society of Electrical and Electronic Engineering (IEEE), the American Institute of Biological and Medical Engineering (AIMBE) and the Acoustical Society of America (ASA). Elisa is recipient of the CAREER award by the National Science Foundation (NSF), the Nagy award by the National Institutes of Health (NIH), the Technological Achievement Award by the IEEE Engineering in Medicine and Biology society (EMBS), the Carl Hellmuth Hertz Ultrasonics Award by the IEEE Society in Ultrasonics, Ferroelectrics and Frequency Control (UFFC), the Janette and Armen Avanessians Diversity Award by Columbia university and the Elisabeth Papazoglou Inspired Leadership Award by Drexel University as well as additional recognitions by the American Heart Association, the Acoustical Society of America, the American Institute of Ultrasound in Medicine, the American Association of Physicists in Medicine, the Wallace H. Coulter foundation, the Bodossaki foundation, the Society of Photo-optical Instrumentation Engineers (SPIE) and the Radiological Society of North America (RSNA). Elisa also serves as President-Elect of the International Society of Therapeutic Ultrasound.